Related Experiment Video
Updated: Mar 29, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Prognostic Value of HALP Score in Rheumatic Mitral Stenosis: A Long-Term Follow-up Study
Ahmet Ferhat Kaya1, Görkem Ayhan1, Veysi Can
1Department of Cardiology, Van Regional Education and Research Hospital, Van, Turkey.
Insights
The hemoglobin-albumin-lymphocyte-platelet (HALP) score shows modest prognostic value for major adverse cardiac and cerebrovascular events (MACCE) in rheumatic mitral stenosis (RMS) patients. It is a useful complementary tool but not an independent predictor alone.
Area of Science:
- Cardiology
- Clinical Medicine
- Biomarkers
Background:
- Rheumatic mitral stenosis (RMS) requires accurate prognostic tools for patient management.
- The hemoglobin-albumin-lymphocyte-platelet (HALP) score is a composite biomarker with potential prognostic implications.
Purpose of the Study:
- To investigate the prognostic value of the HALP score in predicting major adverse cardiac and cerebrovascular events (MACCE) in patients with RMS.
Main Methods:
- Retrospective analysis of 169 RMS patients with a median follow-up of 124 months.
- Assessment of HALP score's predictive performance using ROC analysis, Cox regression, and Kaplan-Meier survival analysis.
- Primary endpoint defined as MACCE.
Main Results:
- The HALP score demonstrated a statistically significant, albeit modest, ability to predict MACCE (AUC=0.644, p=0.037).
- Lower HALP scores were associated with a significantly higher incidence of MACCE (log-rank p=0.015).
- The HALP score was not an independent predictor in multivariable analysis (p=0.076).
Conclusions:
- The HALP score can serve as a simple, cost-effective complementary tool for risk stratification in RMS patients.
- Its prognostic value is limited when used in isolation.
- Interpretation alongside established clinical and echocardiographic parameters is recommended.
Objective:
This study aimed to evaluate the prognostic value of the hemoglobin-albumin-lymphocyte-platelet (HALP) score in patients with rheumatic mitral stenosis (RMS).
Methods:
A total of 169 patients with RMS were retrospectively analyzed over a median follow-up period of 124 months (IQR: 96-148). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE). The predictive performance of the HALP score was assessed using receiver operating characteristic (ROC) analysis, Cox regression, and Kaplan-Meier survival analysis.
Results:
The HALP score demonstrated a modest but statistically significant ability to predict MACCE (AUC = 0.644, p = 0.037). The optimal cut-off value was 35.65, with a sensitivity of 60.4% and specificity of 38.1%. Patients with lower HALP scores had a significantly higher incidence of MACCE (log-rank p = 0.015). However, in multivariable analysis, the HALP score was not identified as an independent predictor (p = 0.076).
Conclusion:
The HALP score may serve as a simple and cost-effective complementary tool for risk stratification in patients with RMS. However, its prognostic value appears limited when used alone, and it should be interpreted alongside established clinical and echocardiographic parameters.
More Related Videos
Related Concept Videos
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Stenosis IV: Nursing Management
Mitral Stenosis I: Introduction
Mitral Stenosis III: Medical Management
Mitral Valve Prolapse II: Assessment and Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

